Part One: Updates in Management of Atrial Fibrillation
Part Two: Considerations for Anticoagulation in Unique Populations and Scenarios

• Series Overview
• Program Content
• Faculty
• Financial Relationship Disclosures
• Target Audience and Learning Objectives
• Continuing Pharmacy Education Credit
• BCPS Specialty Recertification Credit
• Technical Requirements
• Commercial Support
• Fees

Clinical Reasoning Series in Pharmacotherapy has been approved by the Board of Pharmacy Specialties (BPS) as one component of the professional development programs developed by ACCP for recertification of the Board Certified Pharmacotherapy Specialist (BCPS).

This educational series explores cutting-edge, contemporary therapeutic topics, and demonstrates scientifically sound clinical reasoning and decision-making. It employs learning activities designed to advance the participants' skills and abilities to critically evaluate the scientific evidence and to effectively incorporate into daily practice significant findings that lead to effective and safe patient care.

The program will consist of several educational activities and is presented in two parts with each part containing:

• streaming audio/slide synchronized presentations
• downloadable mp3 audio files
• downloadable mp4 video files
• downloadable/printable PDFs of presentation slides
• Continuing Pharmacy Education (CPE) credit
• Recertification Credit - Available with Specialty Recertification package

Release date: November 9, 2022
BCPS credit expiration date: November 9, 2023
ACPE credit expiration date: November 9, 2025

Part One: Updates in Management of Atrial Fibrillation

Board Certified Pharmacotherapy Specialists are at the forefront of treatment of patients with atrial fibrillation (AF). Recommendations regarding rate versus rhythm control as well as the role of direct oral anticoagulants in valvular AF has evolved over the past several years. There is emerging data suggesting the early use of rhythm control in AF patients as well as the potential role of DOACs in patients with valvular AF.

This program will explore the following topics:

• Evolution of clinical evidence for rate vs. rhythm control in the treatment of atrial fibrillation
• Patient characteristics that support early rhythm-control therapy
• Overview of the evolution of the definition of valvular atrial fibrillation
• Discuss an evidence-based anticoagulation regimen for treating patients with valvular atrial fibrillation

Part Two: Considerations for Anticoagulation in Unique Populations and Scenarios

Board Certified Pharmacotherapy Specialists are commonly involved with the decision of choosing the appropriate anticoagulation strategy in patients with unique indications such as left ventricular (LV) thrombus. In addition, pharmacists are also often impacted by drug shortages, supply chain issues, regulatory constraints, and medication safety considerations which influence the use DOACs and other anticoagulants.

This program will explore the following topics:

• Current practice guideline recommendations in regard to prophylaxis and treatment of patients with left ventricular thrombus
• Assess the off-label use of DOACs in this patient population
• Provide an overview of the regulatory and safety considerations with anticoagulants
• Focus on the role of anticoagulants in niche patient populations as well as the safety considerations and risk mitigation strategies with anticoagulant agents

Clinical Reasoning Series in Pharmacotherapy – Program Chair

	Audrey J. Littlefield, Pharm.D., MBA, BCPS, BCCCP Clinical Pharmacy Manager Cardiothoracic ICU at NewYork-Presbyterian Hospital Weill Cornell Medical Center New York, New York

Clinical Reasoning Series in Pharmacotherapy – Part One: Updates in Management of Atrial Fibrillation

	Keith Anderson, Pharm.D., BCCP Clinical Pharmacist Cleveland Clinic Cleveland, Ohio
	Stephanie Dwyer Kaluzna, Pharm.D., BCCP Clinical Assistant Professor PGY2 Cardiology Residency Program Director University of Illinois at Chicago College of Pharmacy Cardiovascular Clinical Pharmacist University of Illinois Hospital and Health Sciences System Chicago, Illinois

Clinical Reasoning Series in Pharmacotherapy – Part Two: Considerations for Anticoagulation in Unique Populations and Scenarios

	Taylor Chuich, Pharm.D., BCPS Pharmacy Manager New York-Presbyterian Hospital Columbia University Medical Center New York, New York
	Jackie Paige Rowe, Pharm.D., BCPS Critical Care Clinical Pharmacist St. Joseph’s University Medical Center Paterson, New Jersey

Disclosures 

TARGET AUDIENCE
The target audience for Clinical Reasoning Series in Pharmacotherapy is the pharmacist practicing in a clinical setting as a Board Certified Pharmacotherapy Specialist (BCPS) looking to earn recertification credit, and those clinicians seeking additional information on the topics covered.

LEARNING OBJECTIVES
At the conclusion of Part One: Updates in Management of Atrial Fibrillation, the participant should be able to:

1. Describe the evolution of clinical evidence for rate versus rhythm control in the treatment of atrial fibrillation.
2. Identify patient characteristics that support early rhythm-control therapy for the treatment of atrial fibrillation.
3. Describe the evolution of the definition of valvular atrial fibrillation.
4. Develop an evidence-based anticoagulation treatment regimen for a patient with valvular atrial fibrillation.

At the conclusion of Part Two: Considerations for Anticoagulation in Unique Populations and Scenarios, the participant should be able to:

1. Describe the current practice guideline recommendations in regards to prophylaxis and treatment of left ventricular thrombus.
2. Assess published literature in the off label use of direct oral anticoagulant therapy for left ventricular thrombus.
3. Describe the evolution of anticoagulant use.
4. Discuss safety considerations and risk mitigation strategies with anticoagulant agents.

The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Clinical Reasoning Series in Pharmacotherapy – Part One: Updates in Management of Atrial Fibrillation
Activity Number: 0217-0000-22-228-H01-P
Contact Hours: 3.00
Activity Type: Application-Based Activity

Clinical Reasoning Series in Pharmacotherapy – Part Two: Considerations for Anticoagulation in Unique Populations and Scenarios
Activity Number: 0217-0000-22-229-H01-P
Contact Hours: 3.00
Activity Type: Application-Based Activity

Methods and CE Requirements

ACPE Continuing Pharmacy Education Credit
To be eligible to earn continuing pharmacy education credit, participants must purchase the product, review all content, successfully complete, submit and pass the Web-based posttest associated with each module by November 9, 2025. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

National Association of Boards of Pharmacy - CPE Monitor Service

Provided through the collaborative efforts of the National Association of Boards of Pharmacy (NABP), the Accreditation Council for Pharmacy Education (ACPE), and ACPE-accredited providers, the CPE Monitor Service allows you to electronically keep track of continuing pharmacy education (CPE) credits from ACPE-accredited providers. ACPE-accredited providers, like ACCP, are responsible for transmitting this information to NABP to be stored in the CPE Monitor system. Statements of credit will be available at CPE Monitor, nabp.pharmacy/cpe-monitor-service/, within 2–3 business days after completion of this activity. For more information on CPE Monitor please visit nabp.pharmacy/cpe-monitor-service/.

To transfer these credits to CPE Monitor on your behalf your NABP e-Profile ID Number and date of birth must be listed on your ACCP account. To verify or update this information in your ACCP account, visit Licensure/Certification. Be sure to save your changes at the bottom of the page.

Some international pharmacists do not use the CPE Monitor service. To verify or update this information in your ACCP account, visit Licensure/Certification. Check the box “I am an international pharmacist or I am not licensed to practice in the United States, and do not have an NABP e-Profile ID.” Be sure to save your changes at the bottom of the page.

To be eligible to earn BCPS recertification credit, participants must purchase the recertification version of this course, review all content, successfully complete, submit and pass the Web-based posttest associated with each module by November 9, 2023. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

The passing point to earn BCPS recertification credit is based on an expert analysis of the assessment items in each posttest module. Any posttest submitted before the BCPS posttest deadline that meets this passing point will earn BCPS recertification credits. These credits will be assigned as of the date of test submission. For statements of recertification credit, visit www.bpsweb.org.

All participants must have a Board of Pharmacy Specialties (BPS) board certification credential number, BPS ID Number, and a BPS expiration date on file with ACCP for reporting purposes. To verify or update this information in your ACCP account, visit Licensure/Certification. Be sure to save your changes at the bottom of the page.

Questions regarding the number of hours required for BCPS recertification should be directed to BPS at (202) 946-5026 or www.bpsweb.org. The ACCP Recertification Dashboard is a free online tool that can track recertification credits as they are earned through ACCP and schedule new opportunities for credits from upcoming ACCP professional development programs.

• Internet browser
• Adobe Reader (available free)

The American College of Clinical Pharmacy does not solicit or accept external commercial/financial support for its continuing pharmacy education activities. No commercial/financial support has been solicited or accepted for this activity.